低性周期性:一个为期3年的随访研究
Sonja Holm-Yildiz1, Thomas Krag2, Nanna Witting2
1Copenhagen Neuromuscular Center, Department of Neurology 8077, Rigshospitalet, University of Copenhagen, Inge Lehmanns Vej 8, 2100, Copenhagen, Denmark. Sonja.desiree.holm-yildiz@regionh.dk.
Journal of neurology
|September 1, 2023
概括
初级低血压周期性 (HypoPP) 是一种渐进的肌肉病,即使在没有发作的患者中也是如此. 这种通道病症可以随着时间的推移而恶化,显示肌肉力量下降和脂肪替代.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 肌肉生理学 肌肉生理学
背景情况:
- 初级低血压周期性 (HypoPP) 是一种遗传的通道病变,通常与CACNA1S突变有关.
- 缺血PP表现出不同的表型,包括周期性 (PP),永久性软弱 (PW) 和混合性软弱 (MW).
- 人们对HypoPP的自然史和长期进展仍然不完全了解.
研究的目的:
- 调查HypoPP.个体的自然史和疾病进展.
- 在3年的随访期内评估肌肉强度和肌肉组成的变化.
- 为了确定HypoPP是否是一种渐进的肌肉病变,无论的发作频率如何.
主要方法:
- 一项为期3年的随访研究,涉及患有导致HypoPP的CACNA1S突变的个体.
- 使用MRC尺度进行手动肌肉强度测试.
- 全身肌肉MRI (水星得分) 评估脂肪的替代.
主要成果:
- 11名患者的肌肉力量下降;四人在随访期间没有发作.
- 在27名患者中观察到肌肉脂肪更换的增加;八名患者没有发作.
- 疾病的进展,包括力量下降和脂肪透,甚至发生在没有发作史的患者中.
结论:
- 低PP可以是一个渐进的肌肉病.
- 在HypoPP患者中,肌肉衰弱和脂肪替代可能会发生,而不依赖于发作.
- 调查结果强调了HypoPP的渐进性质,强调了长期监测的必要性.
相关概念视频
Acute Kidney Injury III: Clinical Manifestations
29
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
29
Antiepileptic Drugs: Potassium Channel Activators
210
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
210


